<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780169</url>
  </required_header>
  <id_info>
    <org_study_id>OTT 06-08</org_study_id>
    <nct_id>NCT00780169</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I Study of Sorafenib (Nexavar®) in Combination With FOLFIRI as First Line Therapy for Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, the maximum tolerated dose and the&#xD;
      recommended dose for phase II studies of a chemotherapy-combination of sorafenib, irinotecan,&#xD;
      and 5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) as first-line treatment for metastatic&#xD;
      colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A standard phase I dose escalation design with three to six patients per dose level will be&#xD;
      used. The first three patients will receive chemotherapy at the dose level 1 for 4 weeks (2&#xD;
      FOLFIRI regimen). The dose will be escalated for the next patients by one dose level if none&#xD;
      of the three patients at a dose level experience a dose-limiting toxicity (DLT) during the&#xD;
      first six weeks. Intrapatient dose escalation is not allowed. If one of the three patients&#xD;
      has a DLT, an additional three patients will be enrolled at this dose level and the dose will&#xD;
      be escalated if no additional patients experience a DLT. Otherwise, the dose escalation will&#xD;
      be stopped, and the last dose will be regarded as the Maximum Administered Dose (MAD). The&#xD;
      preceding dose level will be declared the Maximum Tolerated Dose (MTD). This dose level will&#xD;
      be the recommended dose (RD). At least 6 patients will be treated at the MTD. The cohort at&#xD;
      the MTD dose level can be expanded to as many as 12 patients to gain experience with the&#xD;
      toxicities and efficacy of Sorafenib + FOLFIRI combination over a broad patient range.&#xD;
      Patients experiencing a DLT during the first cycle of treatment will have the drug withheld.&#xD;
      They will be eligible for repeated treatment at a lower dose or treated off protocol.&#xD;
&#xD;
      Treatment is to be discontinued in cases of serious or unmanageable toxicity or request by&#xD;
      the patient. Otherwise therapy will continue until clinically or radiologically documented&#xD;
      disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity spectrum of Sorafenib (MTD, DLT) and the recommended dose (RD) for phase II studies of Sorafenib when combined with FOLFIRI in first line patients with metastatic colorectal cancer (mCRC)</measure>
    <time_frame>each cycle - 4 weeks; continuous monitoring of AEs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Irinotecan in the presence of Sorafenib</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response according to Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>every 2 cycles - 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression and Overall Survival</measure>
    <time_frame>each cycle - 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>sorafenib +FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a Phase I safety study. There is only one arm of FOLFIRI administered every 14 days (2 week schedule) and sorafenib administered orally, twice daily continuously. First cycle sorafenib began at day +2 to FOLFIRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib + FOLFIRI</intervention_name>
    <description>escalating doses of sorafenib and irinotecan&#xD;
sorafenib starting dose 400 mg/day&#xD;
irinotecan starting dose 80 mg/m2 on day 1</description>
    <arm_group_label>sorafenib +FOLFIRI</arm_group_label>
    <other_name>sorafenib - Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic colorectal cancer&#xD;
&#xD;
          -  Histopathological verification of the primary tumor&#xD;
&#xD;
          -  Measurable disease according to RESIST criteria&#xD;
&#xD;
          -  Response Evaluation Criteria in Solid Tumors (ECOG) performance status ≤ 2&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Women of childbearing potential must have had a negative pregnancy test within 7 days&#xD;
             prior to start of treatment. Women of childbearing potential and men must agree to use&#xD;
             adequate contraception prior to study entry and for the duration of study&#xD;
             participation.&#xD;
&#xD;
          -  Patients may have had prior adjuvant chemotherapy with fluoropyrimidines WITHOUT&#xD;
             pelvic radiotherapy.&#xD;
&#xD;
          -  Radiation: Patients may have had prior palliative radiation therapy to NO more than&#xD;
             50% of the areas bearing of bone marrow stores.&#xD;
&#xD;
          -  Adequate organ and marrow function : Hemoglobin &gt; 9.0 g/dl; absolute neutrophil count&#xD;
             (ANC) &gt;1,500/mm3; absolute granulocyte count(AGC) &gt; 1.5 x 109 /L; Platelets &gt; 100 x&#xD;
             109 /L; Serum creatinine and creatinine clearance within upper normal limit; Bilirubin&#xD;
             &lt; 1.0 x upper normal limit, &lt; 2.5 x upper normal limit if documented liver metastases;&#xD;
             aspartate aminotransferase (AST) &lt; 2.5 x upper normal limit, &lt; 5 x upper normal limit&#xD;
             if documented liver metastases&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or concurrent malignancies&#xD;
&#xD;
          -  Patients with central nervous system (CNS) metastases&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or anticancer therapy&#xD;
&#xD;
          -  Previous chemotherapy for advanced and/or metastatic disease&#xD;
&#xD;
          -  Previous adjuvant therapy with irinotecan or targeted agents&#xD;
&#xD;
          -  Previous Sorafenib therapy&#xD;
&#xD;
          -  Previous full dose curative pelvic radiotherapy&#xD;
&#xD;
          -  History of cardiovascular disease, cerebral ischemia infarction or hemorrhage,&#xD;
             Gilbert's disease, HIV positivity&#xD;
&#xD;
          -  Unable to be compliant with the procedures in the protocol&#xD;
&#xD;
          -  Currently use prohibited medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean A Maroun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2008</study_first_posted>
  <last_update_submitted>May 9, 2013</last_update_submitted>
  <last_update_submitted_qc>May 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

